Key Points
- CEO sale: Allogene CEO David Chang sold 95,269 shares on Feb. 2 at an average price of $1.80 for about $171,484, reducing his stake by 1.8% to 5,185,862 shares (SEC Form 4 filed).
- Coordinated insider selling: Several other senior executives (EVP, CFO and multiple SVPs) sold shares the same day, trimming individual holdings by roughly 1.8–5.8%; these simultaneous sales could be a negative near‑term signal and may pressure the stock.
- Market and analyst context: ALLO trades around $1.80 with a market cap near $404 million, while analysts have a consensus rating of "Moderate Buy" and a $8.40 average price target.
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Benjamin Machinas Beneski sold 7,549 shares of Allogene Therapeutics stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $1.73, for a total transaction of $13,059.77. Following the sale, the senior vice president owned 210,172 shares in the company, valued at approximately $363,597.56. This represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Allogene Therapeutics Stock Performance
Shares of NASDAQ ALLO opened at $1.79 on Thursday. The firm has a 50 day moving average price of $1.51 and a two-hundred day moving average price of $1.32. The stock has a market cap of $401.14 million, a P/E ratio of -1.84 and a beta of 0.60. Allogene Therapeutics, Inc. has a 52-week low of $0.86 and a 52-week high of $3.78.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. Analysts predict that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research firms have issued reports on ALLO. Citizens Jmp upgraded shares of Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a report on Friday, January 9th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Allogene Therapeutics in a research report on Wednesday, October 8th. UBS Group assumed coverage on Allogene Therapeutics in a research note on Wednesday, January 7th. They issued a "buy" rating and a $8.00 price target on the stock. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of Allogene Therapeutics in a research report on Friday, October 10th. Finally, Wall Street Zen upgraded shares of Allogene Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, November 28th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $8.40.
Check Out Our Latest Stock Analysis on Allogene Therapeutics
Key Allogene Therapeutics News
Here are the key news stories impacting Allogene Therapeutics this week:
- Positive Sentiment: The stock rallied on news the company has an extended cash runway and reported progress in its CAR‑T trials, which reduces near‑term financing risk and improves outlook for clinical milestones. Read More.
- Neutral Sentiment: Reported short‑interest figures appear anomalous (shown as 0 shares and NaN change), so there is no clear signal of rising short pressure from the latest data — treat short‑interest data as unreliable until clarified. Read More.
- Negative Sentiment: Several senior executives sold shares on Feb. 2, including CEO David D. Chang (95,269 shares at ~$1.80, ≈$171k proceeds) and other C‑suite/SVPs (multiple Form 4 filings). While each sale represents a small percentage reduction in individual holdings, coordinated insider selling can damp investor sentiment and add near‑term selling pressure. Read More.
Institutional Trading of Allogene Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new position in Allogene Therapeutics during the 1st quarter valued at $85,000. Goldman Sachs Group Inc. increased its position in shares of Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company's stock valued at $8,547,000 after acquiring an additional 3,747,397 shares during the last quarter. Jane Street Group LLC lifted its holdings in Allogene Therapeutics by 578.7% during the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company's stock worth $1,630,000 after acquiring an additional 952,158 shares during the period. Vanguard Personalized Indexing Management LLC lifted its holdings in Allogene Therapeutics by 183.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 71,688 shares of the company's stock worth $81,000 after acquiring an additional 46,398 shares during the period. Finally, R Squared Ltd purchased a new position in Allogene Therapeutics in the second quarter worth $37,000. 83.63% of the stock is owned by institutional investors.
About Allogene Therapeutics
(
Get Free Report)
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.
The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
